Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice.
Immunotherapy with antibodies against respiratory syncytial virus (RSV) is a treatment option given the absence of any vaccine or other available satisfactory treatment. We selected one of our monoclonal antibodies, RS-348, that is highly neutralizing. We showed that a single peptide (PEP3H) derived from complementarity-determining region 3 (CDR3) of its heavy chain was capable of neutralizing the virus in vitro. When intranasally administered 24 h before challenge, this peptide protected BALB/c mice against RSV lung infection. These results indicate that a single CDR can be effective against RSV infection.
Bourgeois
C
C
Laboratoire de Microbiologie médicale et moléculaire, Faculté de Médecine, Dijon, France.
Bour
J B
JB
Aho
L S
LS
Pothier
P
P
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000737:chemistry / Q000235:genetics; D000914:Antibodies, Viral / Q000008:administration & dosage* / Q000737:chemistry / Q000235:genetics; D005260:Female; D007135:Immunoglobulin Variable Region / Q000008:administration & dosage* / Q000737:chemistry / Q000235:genetics; D007167:Immunotherapy; D066298:In Vitro Techniques; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D012136:Respiratory Syncytial Viruses / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D007135:Immunoglobulin Variable Region